JP2019508044A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508044A5
JP2019508044A5 JP2018546653A JP2018546653A JP2019508044A5 JP 2019508044 A5 JP2019508044 A5 JP 2019508044A5 JP 2018546653 A JP2018546653 A JP 2018546653A JP 2018546653 A JP2018546653 A JP 2018546653A JP 2019508044 A5 JP2019508044 A5 JP 2019508044A5
Authority
JP
Japan
Prior art keywords
nucleic acid
recombinant nucleic
acid vector
sequence
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018546653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/023117 external-priority patent/WO2017161360A2/en
Publication of JP2019508044A publication Critical patent/JP2019508044A/ja
Publication of JP2019508044A5 publication Critical patent/JP2019508044A5/ja
Pending legal-status Critical Current

Links

JP2018546653A 2016-03-18 2017-03-20 樹状細胞感染のための多モードベクター Pending JP2019508044A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662310551P 2016-03-18 2016-03-18
US62/310,551 2016-03-18
US201662313596P 2016-03-25 2016-03-25
US62/313,596 2016-03-25
PCT/US2017/023117 WO2017161360A2 (en) 2016-03-18 2017-03-20 Multimodal vector for dendritic cell infection

Publications (2)

Publication Number Publication Date
JP2019508044A JP2019508044A (ja) 2019-03-28
JP2019508044A5 true JP2019508044A5 (https=) 2020-04-16

Family

ID=59850551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018546653A Pending JP2019508044A (ja) 2016-03-18 2017-03-20 樹状細胞感染のための多モードベクター

Country Status (11)

Country Link
US (1) US20210198689A1 (https=)
EP (1) EP3430148A4 (https=)
JP (1) JP2019508044A (https=)
KR (1) KR20180118198A (https=)
CN (1) CN109312364A (https=)
AU (1) AU2017233072B2 (https=)
CA (1) CA3016389A1 (https=)
IL (1) IL261812A (https=)
MX (1) MX2018011306A (https=)
SG (1) SG11201808058PA (https=)
WO (1) WO2017161360A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201414021D0 (en) 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
AU2016311444B2 (en) 2015-08-25 2019-02-07 Nantomics, Llc Systems and methods for high-accuracy variant calling
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
EP4101447A1 (en) 2016-06-30 2022-12-14 Nant Holdings IP, LLC Nant cancer vaccine
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
DK3630143T5 (da) 2017-06-01 2024-09-02 Akamis Bio Ltd Onkolytisk virus og fremgangsmåde
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1137792T3 (da) * 1998-12-09 2007-09-10 Us Gov Health & Human Serv En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf
EP1385538B1 (en) * 2001-04-05 2013-01-30 The Johns Hopkins University Chimeric Vaccines comprising the lumenal domain of LAMP-1 or LAMP-2
WO2003039591A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
CN1761757A (zh) * 2003-01-07 2006-04-19 香港大学 用血管抑制素协同加强腺伴随病毒介导的b7.1免疫接种以根除扩散的肝转移性肿瘤
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
JP2008535868A (ja) * 2005-04-14 2008-09-04 ザ ユニバーシティー オブ クイーンズランド 免疫調節組成物およびそのための使用
US20130243731A1 (en) * 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
WO2013033074A2 (en) * 2011-08-31 2013-03-07 St. Jude Children's Research Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
CN102533859A (zh) * 2012-01-12 2012-07-04 中国人民解放军第二军医大学 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用
EP3587455A1 (en) * 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2015063647A1 (en) * 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
AU2014347004B2 (en) * 2013-11-05 2019-08-08 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015112626A1 (en) * 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
KR102499737B1 (ko) * 2014-05-13 2023-02-13 버베리안 노딕 에이/에스 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법

Similar Documents

Publication Publication Date Title
JP2019508044A5 (https=)
Cui et al. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer
JP2019176869A5 (https=)
ES3049406T3 (en) Methods for profiling the t-cell-receptor repertoire
Qiu et al. Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T-cell response and protects mice from melanoma
De Haan et al. Viral gene delivery vectors: the next generation medicines for immune-related diseases
US20180000912A1 (en) Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity
JP2018508567A5 (https=)
JP2018509163A5 (https=)
JP2014523406A5 (https=)
JP2019524773A (ja) 樹状細胞のトランスフェクション及びその方法
WO2017161360A4 (en) Multimodal vector for dendritic cell infection
JP2017525336A5 (https=)
Lin et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles
Goyal et al. Advancing cancer immunotherapy: the potential of mRNA vaccines as a promising therapeutic approach
CN112154204A (zh) 基因工程化的细胞及应用
Pilla et al. Methods for improving the immunogenicity and efficacy of cancer vaccines
CN110859968A (zh) 激活对肿瘤的系统免疫反应的基因生物药物
Shariati et al. mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
JP2015524788A5 (https=)
Crowley et al. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
Bellone et al. Advances in dendritic cell-based therapeutic vaccines for cervical cancer
Garrod et al. DNA vaccines encoding membrane‐bound or secreted forms of heat shock protein 70 exhibit improved potency
CN112867501A (zh) 新的癌抗原和方法
JP2015529629A5 (https=)